Volume 43 Issue 9, September 2025

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Seaport Therapeutics is modifying central nervous system drugs for delivery through the lymphatic system, bypassing first-pass liver metabolism.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Vilya Therapeutics is designing macrocycle drug candidates.

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Freya Biosciences is restoring balance in the vaginal microbiome to improve pregnancy outcomes.

Cultivated meat faces escalating intellectual property (IP) issues as the industry expands, including conventional patent rights, the private IP rights of animal breeders and the Convention on Biological Diversity.

Recent patents relating to pharmaceutical compositions and methods of treatment involving microRNAs.

Recent developments in B cell engineering expand our ability to study human disease and drive progress toward new B cell therapies, balancing challenges in clinical implementation with emerging opportunities.

An engineered clustered regularly interspaced short palindromic repeat ribonucleoprotein delivered in lipid nanoparticles efficiently edits cells in vivo.

Thousands of rare oncogene variants are evaluated using multimodal gene editing screens.

PEER-seq characterizes the drug resistance profiles of thousands of genetic variants.

SCOPE detects low-abundance extracellular vesicle mRNA with high sensitivity for clinical applications.

Gold-siRNA clusters boost the immune response of radiotherapy against primary and distant tumors.

Protein–protein interactomes incorporating structural data predict the functional consequences of disease mutations.

Improved effectors for CRISPRi/CRISPRa are developed following high-throughput screening of transcriptional domains.

Combining expansion microscopy with super-resolution radial fluctuations captures the morphology of single proteins.

Site-specific and efficient RNA editing is achieved with a CasRx editor.

FLiP–MS uses a library of protein–protein interaction markers to understand protein complex dynamics.

Breaking the cycle of institutional betrayal and the culture of silence requires decisive actions to promote transparency, accountability and supportive environments in both academia and industry.

Recent moves of note in and around the biotech and pharma industries.